Status:
COMPLETED
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Lead Sponsor:
Tony Bekaii-Saab
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II study of biweekly (every other week) bevacizumab followed by gemcitabine then infusional 5-fluorouracil in patients with stage III or IV pancreatic cancer. Patients' response will b...
Detailed Description
Rationale: Research indicates that the vascular endothelial growth factor (VEGF), or a substance made by cells that stimulates new blood vessel formation, plays an important role in the growth and met...
Eligibility Criteria
Inclusion
- Males or females age \>=18 years.
- Established histological confirmation of adenocarcinoma of the pancreas.
- Stage III and stage IV will be allowed.
Exclusion
- No prior chemotherapy or radiotherapy allowed except for that given as part of an adjuvant regimen if \>4 weeks have elapsed since the end of therapy. Any prior treatment with antibodies to VEGF.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting the study.
- Pregnant or lactating women.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00417976
Start Date
December 1 2006
End Date
February 1 2011
Last Update
October 1 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Michigan
Ann Arbor, Michigan, United States, 48109
2
The Ohio State University James Cancer Hospital
Columbus, Ohio, United States, 43210